Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) is a blank-check company organized to pursue a business combination in the pharmaceutical and domestic drug-manufacturing sector. The "II" designation marks it as the second SPAC vehicle from the same sponsor group behind its predecessor, Drugs Made In America Acquisition Corp., reflecting a continued thesis around strengthening U.S.-based pharmaceutical supply chains. The company filed an 8-K with the SEC on April 3, 2026 (accession 0001213900-26-039986), indicating ongoing corporate activity while the vehicle remains in its search phase. Units under the DMIIU ticker were listed on Nasdaq, with the SPAC having completed its IPO in 2025. For full filing history, deal timelines, and sponsor profiles on DMIIU and thousands of other SPACs, sign up for SpacDesk.